NuCana Plc(NASDAQ) NCNA

Market Cap$5.24M

Since IPO (2017)-100%

5 Year-100%

1 Year-87%

1 Month-17%

$1.26

+0.00%

+0.00Today

After hours$1.34+$0.08 (+6.35%)

NuCana Plc last closing stock price
Metric	Price	Date
Last close	USD 1.26	2026-07-30

NuCana Plc stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-5.26%	USD 1.33	2026-07-23
1 month	-17.11%	USD 1.52	2026-06-30
3 month	-44%	USD 2.25	2026-05-01
Year to date	-65%	USD 3.60	2025-12-31
1 year	-86.51%	USD 9.34	2025-07-30
3 year	-99.97%	USD 3,800.00	2023-07-31
5 year	-99.99%	USD 10,600.00	2021-07-30
Since inception	-100%	USD 80,750.00	2017-09-28

NuCana Plc Financials at a Glance

Market Cap

$5.24M

Revenue (TTM)

£0.00

Net Income (TTM)

-£30.75M

EPS (TTM)

-$33.32

P/E Ratio

-0.04

Dividend

$0.00

Beta (Volatility)

1.09 (Average)

Dividend

$0.00

Beta (Volatility)

1.09 (Average)

Price

$1.26

Volume

23,238.862

Open

$1.27

Price

$1.26

Volume

23,238.862

Open

$1.27

Previous Close

$1.32

Daily Range

$1.25 - $1.34

52-Week Range

$1.21 - $10.00

Estimated Earnings Date

Aug 13, 2026

Dividend

$0.00

Beta (Volatility)

1.09 (Average)

Price

$1.26

Volume

23,238.862

Open

$1.27

Previous Close

$1.32

Daily Range

$1.25 - $1.34

52-Week Range

$1.21 - $10.00

Estimated Earnings Date

Aug 13, 2026

NCNA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NuCana Plc

NuCana plc is a clinical-stage biopharmaceutical firm focused on developing advanced therapies for oncology. The company leverages its proprietary ProTide technology platform to create innovative drug candidates aimed at treating various types of cancer.

Products and Services

Acelarin, targeting multiple cancer types in various clinical trials
NUC-3373, a ProTide derivative of 5-fluorouracil in Phase I and Ib/II trials
NUC-7738, a nucleoside analog in Phase 1/2 clinical assessment

Growth Outlook

Strong pipeline with multiple ongoing clinical trials for Acelarin
NUC-3373 shows promise in advanced colorectal cancer studies
Collaborations with Cardiff University enhance research capabilities

Financial Highlights

Cash and cash equivalents of £21.53 million as of March 31, 2026
Operating expenses of £4.42 million in Q1 2026
Net income of -£3.87 million for Q1 2026, reflecting ongoing investment in R&D

NuCana plc is positioned in the biotechnology sector, focusing on innovative cancer therapies. The company’s product pipeline, particularly Acelarin, is undergoing extensive clinical evaluations, which could lead to significant advancements in cancer treatment. The financial data indicates a robust cash position, allowing continued investment in research and development. Despite recent net losses, the ongoing clinical trials and strategic collaborations suggest a promising future for the company. Investors may find the potential for growth in the oncology market appealing, especially as the company progresses through its clinical trials.

AI Generated • Jul 2, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Hugh Stephen Griffith, MBA

Website

www.nucana.com

Headquarters

Edinburgh, MD EH12 9DT, GB

NCNA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-153.80%

Return on Capital

-80.43%

Return on Assets

-111.58%

Earnings Yield

-25.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.24M

Shares Outstanding

4.16M

Volume

23.24K

Avg. Volume

50.02K

Financials (TTM)

Gross Profit

£0.00

Operating Income

-£21.68M

EBITDA

-£22.55M

Operating Cash Flow

-£7.54M

Capital Expenditure

-£231.00K

Free Cash Flow

-£7.77M

Cash & ST Invst.

£21.53M

Total Debt

£680.03K

NuCana Plc Performance Analysis

NuCana Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	GBP 0	N/A
2023	2023-12-31	GBP 0	N/A
2024	2024-12-31	GBP 0	N/A
2025	2025-12-31	GBP 0	N/A

NuCana Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

NuCana Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	GBP -3,775.53	-29.5%
2023	2023-12-31	GBP -3,266.68	-13.5%
2024	2024-12-31	GBP -1,635.98	-49.9%
2025	2025-12-31	GBP -17.20	-98.9%

NuCana Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	96.0%
Q3	2025-09-30	98.1%
Q4	2025-12-31	-783.3%
Q1	2026-03-31	-61.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

£0.00

N/A

Gross Profit

£0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.24M

N/A

Market Cap/Employee

$437.00K

N/A

Employees

N/A

Net Income

-£3.87M

-56.3%

EBITDA

-£4.71M

-73.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

£21.53M

+444.7%

Total Debt

£680.03K

+293.1%

Accounts Receivable

£2.17M

-58.0%

Inventory

£0.00

N/A

Long Term Debt

£647.03K

+553.6%

Short Term Debt

£33.00K

-55.4%

Return on Assets

-1.12%

N/A

Return on Invested Capital

-93.95%

N/A

Free Cash Flow

-£3.26M

-3.5%

Operating Cash Flow

-£3.18M

-2.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CLGNCollPlant Biotechnologies Ltd.

CLGNCollPlant Biotechnologies Ltd.$0.30-0.30%

MTVAMetaVia Inc.

MTVAMetaVia Inc.$1.44+0.00%

CASICASI Pharmaceuticals, Inc.

CASICASI Pharmaceuticals, Inc.$0.15+3.08%

CLSDClearside Biomedical, Inc.

CLSDClearside Biomedical, Inc.$0.41+0.00%

LSTALisata Therapeutics, Inc.

LSTALisata Therapeutics, Inc.$0.99-3.88%

GDTCCytoMed Therapeutics Limited

GDTCCytoMed Therapeutics Limited$0.93-5.99%

PASGPassage Bio, Inc.

PASGPassage Bio, Inc.$4.47-0.45%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$200.75+0.03%

AAPLApple

AAPLApple$308.91-0.07%

AMZNAmazon

AMZNAmazon$271.58+0.15%

INTCIntel

INTCIntel$90.20-0.01%

FCUVFocus Universal

FCUVFocus Universal$11.60+5.17%

NOKNokia

NOKNokia$9.14+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.62+0.02%

Questions About NCNA

What is the current price of NuCana Plc?

NuCana Plc is trading at $1.32 per share.

What is the 52-week range for NuCana Plc?

Over the past 52 weeks, NuCana Plc has traded between $1.21 and $10.00.

How much debt does NuCana Plc have?

As of the most recent reporting period, NuCana Plc reported total debt of £896.72K.

How much cash does NuCana Plc have on hand?

NuCana Plc reported £28.39M in cash and cash equivalents in its most recent financial results.

What is NuCana Plc’s dividend yield?

NuCana Plc does not currently have a dividend yield.

NuCana Plc(NASDAQ) NCNA

NuCana Plc Financials at a Glance

NCNA News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About NuCana Plc

NCNA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

NuCana Plc Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NCNA

What is the current price of NuCana Plc?

What is the 52-week range for NuCana Plc?

How much debt does NuCana Plc have?

How much cash does NuCana Plc have on hand?

What is NuCana Plc’s dividend yield?

Premium Investing Services